EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Repurposing Alkylating Agents in Melanoma via ERCC8 Silencing: A Novel Therapeutic Strategy

Silvia Filippi iD, Emma Valeri iD, Valeria Bartolocci iD, Elena Paccosi iD, Diletta Guzzon iD, Luca Proietti-De-Santis iD

Cancers · 17.02.2026 · 18 (4) · 647

DOI: 10.3390/cancers18040647 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 17.02.2026. Verfasst von Silvia Filippi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Molecular Genetics of Aging, Department of Ecological and Biological Sciences, University of Tuscia, 01100 Viterbo, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of University and Research (MUR), Italian Ministry of University and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Melanoma is the deadliest form of skin cancer. Resistance to alkylating agents such as Temozolomide (TMZ) and Dacarbazine (DTIC) limits their clinical benefit, as these drugs remain palliative options when immunotherapies and targeted treatments fail. CSA/ERCC8 is a key component of transcription-coupled nucleotide excision repair (TC-NER), a pathway responsible for removing UV-induced DNA lesions. In principle, loss of a DNA repair factor would be expected to increase carcinogenesis. However, although CSA loss-of-function causes Cockayne Syndrome (CS), affected patients do not exhibit increased skin cancer incidence, suggesting that CSA impairment promotes apoptosis rather than tumor development. This paradox raises the possibility that CSA inhibition may selectively target melanoma cell survival pathways.

Methods

The expression of CSA/ERCC8 was analyzed by qRT-PCR and Western blot. ERCC8 was silenced using antisense oligonucleotides. Cell viability, apoptosis, cell cycle progression, drug sensitivity, and DNA damage were assessed by functional assays, including IC50 determination and Bliss analysis for drug interactions.

Results

We identified CSA/ERCC8 as a driver of melanoma chemoresistance. CSA was markedly overexpressed in primary and metastatic melanoma cells. ERCC8 silencing reduced proliferation, induced apoptosis, and significantly enhanced sensitivity to low doses of TMZ and DTIC while sparing normal cells.

Conclusions

CSA represents a promising therapeutic target to overcome chemoresistance in melanoma. Its inhibition enhances the efficacy and selectivity of alkylating agents, supporting its potential as a salvage strategy for refractory disease and warranting further preclinical and clinical investigation.

Schlagwörter

Stichwörter der Autor:innen

DNA damage response (DDR)DNA repair targetingERCC8antisense oligonucleotides (ASOs)chemoresistancecockayne syndrome A proteinmelanomasynthetic lethality

Autor:innen und Institutionen

  • Unit of Molecular Genetics of Aging, Department of Ecological and Biological Sciences, University of Tuscia, 01100 Viterbo, Italy.

ORCID-Profile: Silvia Filippi, Emma Valeri, Valeria Bartolocci, Elena Paccosi, Diletta Guzzon, Luca Proietti-De-Santis

Förderung

  • Ministry of University and Research (MUR)
  • Italian Ministry of University and Research

Zitieren

APA

Filippi, S., Valeri, E., Bartolocci, V., Paccosi, E., Guzzon, D., & Proietti-De-Santis, L. (2026). Repurposing Alkylating Agents in Melanoma via ERCC8 Silencing: A Novel Therapeutic Strategy. Cancers, 18(4), 647. https://doi.org/10.3390/cancers18040647

Vancouver

Filippi S, Valeri E, Bartolocci V, Paccosi E, Guzzon D, Proietti-De-Santis L. Repurposing Alkylating Agents in Melanoma via ERCC8 Silencing: A Novel Therapeutic Strategy. Cancers. 2026;18(4):647. doi:10.3390/cancers18040647

BibTeX
@article{Filippi2026,
  author = {Filippi, Silvia and Valeri, Emma and Bartolocci, Valeria and Paccosi, Elena and Guzzon, Diletta and Proietti-De-Santis, Luca},
  title = {Repurposing Alkylating Agents in Melanoma via ERCC8 Silencing: A Novel Therapeutic Strategy},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {4},
  pages = {647},
  doi = {10.3390/cancers18040647}
}
Kostenlos starten →